Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives. Structure-activity relationships

Biochemical Pharmacology

Volumn 54, Issue 12, 1997, Pages 1361-1369

  Scorza, Ma Cecilia ^a   Carrau, Cecilia ^a   Silveira, Rodolfo ^a   Zapata Torres, Gerald ^b   Cassels, Bruce K ^b   Reyes Parada, Miguel ^a  

^a INSTITUTO DE INVESTIGACIONES BIOLÓGICAS CLEMENTE ESTABLE   (Uruguay)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

Amphetamine derivatives; Antidepressants; MAO inhibitors; Monoamine oxidase; Phenylisopropylamine derivatives; Structure activity relationships

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; AMIFLAMINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMPHETAMINE; AMPHETAMINE DERIVATIVE; CLORGYLINE; SELEGILINE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN MITOCHONDRION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENZYME INHIBITION; HIPPOCAMPUS; IN VITRO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAPHE NUCLEUS; RAT; STRUCTURE ACTIVITY RELATION;

AMPHETAMINES; ANIMALS; BRAIN CHEMISTRY; HYDROXYINDOLEACETIC ACID; MALE; MONOAMINE OXIDASE INHIBITORS; RATS; SEROTONIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0000206859     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00405-X     Document Type: Article

References (51)

1. Murphy DL. Substrate-selective monoamine oxidases. Biochem Pharmacol. 27:1978;1889-1893.
2. Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol. 17:1968;1285-1297.
3. Bach AWJ, Lan NC, Johanson DL, Abell CW, Bembenek ME, Kwan SW, Seeburg PH, Shih JC. cDNA cloning of human monoamine oxidase A and B Molecular basis of differences in enzymatic properties . Proc Natl Acad Sci USA. 85:1988;4934-4938.
4. Youdim MBH. Implications of MAO-A and MAO-B inhibitors for antidepressant therapy. Mod Probl Pharmacopsychiatry. 19:1983;63-74.
5. Murphy DL, Aulakh CS, Garrik NA, Sunderland T. Monoamine oxidase inhibitors as antidepressants Implication for the mechanism of action of antidepressants and the psychobiology of the affective disorders and some related disorders . Meltzer HY. Psychopharmacology The Third Generation of Progress . 1987;545-552 Raven Press, New York.
6. Shulman KI. Dietary issues and the "irreversible" MAOIs. Kennedy SH. Clinical Advances in Monoamine Oxidase Inhibitor Therapies. 1994;111-124 American Psychiatric Press, Washington, DC.
7. Möller H-J, Paykel ES. Renaissance of Monoamine Oxidase Inhibitors The New Selective and Reversible Generation . 1992;Royal Society of Medicine, London.
8. Waldmeier PC, Amrein R, Schmid-Burgk W. Pharmacology and pharmacokinetics of brofaromine and moclobemide in animals and humans. Kennedy SH. Clinical Advances in Monoamine Oxidase Inhibitor Therapies. 1994;33-59 American Psychiatric Press, Washington, DC.
9. Bieck PR, Antonin K-H. Tyramine potentiation during treatment with MAOIs. Kennedy SH. Clinical Advances in Monoamine Oxidase Inhibitor Therapies. 1994;83-110 American Psychiatric Press, Washington, DC.
10. Mantle TJ, Tipton KF, Garrett NJ. Inhibition of monoamine oxidase by amphetamine and related compounds. Biochem Pharmacol. 25:1976;2073-2077.
11. Florvall L, Ask A-L, Ögren S-O, Ross SB. Selective MAO inhibitors. Compounds related to 4-aminophenethylamine. J Med Chem. 21:1978;56-63.
12. Florvall L, Ask A-L, Fagervall I, Ross SB. Selective MAO inhibitors. 4. 4-Aminophenethylamine derivatives with neuron selective action. J Med Chem. 29:1986;2250-2256.
13. Reyes-Parada M, Scorza MC, Silveira R, Dajas F, Costa G, Tipton KF, Cassels BK. Monoamine oxidase inhibitory effects of some 4-aminophenethylamine derivatives. Biochem Pharmacol. 47:1994;1365-1371.
14. Fuller RW, Hemrick-Luecke SK. Influence of ring and side chain substituents on the selectivity of amphetamine as a monoamine oxidase inhibitor. Res Commun Subst Abuse. 3:1982;159-164.
15. Arai Y, Kim SK, Kinemuchi H, Tadano T, Satoh S-E, Satoh N, Kisara K. Inhibition of brain type A monoamine oxidase and 5-hydroxytryptamine uptake by two amphetamine metabolites, p-hydroxyamphetamine and p-hydroxynorephedrine. J Neurochem. 55:1990;403-408.
16. Green AL, El Hait MAS. p-Methoxyamphetamine, a potent reversible inhibitor of type-A monoamine oxidase in vitro and in vivo. J Pharm Pharmacol. 32:1980;262-266.
17. Kumar Y, Florvall L, Ask A-L, Ross SB, Holm A-C, Ögren S-O. Selective monoamine oxidase inhibitors. Compounds derived from phenethylamine and 1-phenoxy-2-aminopropane. Acta Pharm Suec. 20:1983;349-364.
18. Florvall L, Ask A-L, Ross SB, Ögren S-O, Holm A-Ch. Selective monoamine oxidase inhibitors. II. 4-Aminophenylalkylamine derivatives. Acta Pharm Suec. 20:1983;255-270.
19. Florvall L, Kumar Y, Ask A-L, Fagervall I, Ross SB. Selective MAO inhibitors. 3. Cyclic compounds related to 4-aminophenethylamine. Preparation and neuron selective action of some 5-(2-aminoethyl)-2,3-dihydroindoles. J Med Chem. 29:1986;1406-1412.
20. Ask A-L, Fagervall I, Florvall L, Ross SB, Ytterborn S. Inhibition of MAO in 5-hydroxytryptaminergic neurons by substituted p-aminophenylalkylamines. Br J Pharmacol. 85:1985;683-690.
21. Nichols DE, Glennon RA. Medicinal chemistry and structure-activity relationships of hallucinogens. Jacobs BL. Hallucinogens Neurochemical, Behavioral and Clinical Perspectives . 1984;95-142 Raven Press, New York.
22. Glennon RA, Westkaemper RB, Bartyzel P. The medicinal chemistry of serotonergic agents. Peroutka SJ. Serotonin Receptor Subtypes. Basic and Clinical Aspects. 1991;19-64 Wiley-Liss, New York.
23. Nichols DE. Medicinal chemistry and structure-activity relationships. Cho AK, Segal DS. Amphetamine and Its Analogs. Psychopharmacology, Toxicology and Abuse. 1994;3-41 Academic Press, San Diego, CA.
24. Nichols DE, Marona-Lewicka D, Huang X, Johnson MP. Novel serotonergic agents. Drug Des Discov. 9:1993;299-312.
25. Shulgin AT, Shulgin A. PIHKAL: Phenethylamines I Have Known and Loved. 1991;Transform Press, Berkeley, CA.
26. Sepúlveda S, Valenzuela R, Cassels BK. Potential psychotomimetics. New bromoalkoxy-amphetamines. J Med Chem. 15:1972;413-415.
27. Gómez-Jeria JS, Cassels BK, Saavedra-Aguilar JC. A quantum-chemical and experimental study on the hallucinogen (±)-1-(2,5-dimethoxy-4-nitrophenyl)-2-aminopropane (DON). Eur J Med Chem. 22:1987;433-437.
28. Jara AN, Torres MA, Cassels BK, Rezende MC. Some fluoro and nitro analogues of hallucinogenic amphetamines. Synth Commun. 24:1994;417-426.
29. Squella JA, Cassels BK, Arata M, Bavestrello MP, Núñez-Vergara LJ. Electrochemical oxidation of methylenedioxyamphetamines. Talanta. 40:1993;1379-1384.
30. Glennon RA, Ismaiel AM, Smith JD, Yousif MY, El-Ashmawy M, Herndon JL, Fischer JB, Burke Howie KJ, Server AC. Binding of substituted and conformationally restricted derivatives of N-(3-phenyl-n-propyl)-1-phenyl-2 aminopropane at σ receptors. J Med Chem. 34:1991;1855-1859.
31. 2 serotonin receptors. J Med Chem. 33:1990;1032-1036.
32. Reyes-Parada M, Scorza MC, Silveira R, Dajas F, Cassels BK. 4-Dimethylaminophenethylamine, a sensitive, specific, electrochemically detectable monoamine oxidase-B substrate. Life Sci. 54:1994;1955-1963.
33. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 193:1951;265-275.
34. Fuller RW, Baker JC, Perry KW, Molloy BB. Comparison of 4-chloro-, 4-bromo-, and 4-fluoroamphetamine in rats Drug levels in brain and effects on brain serotonin metabolism . Neuropharmacology. 14:1975;483-488.
35. Fuller RW, Snoddy HD, Snoddy AM, Hemrick SK, Wong DT, Molloy BB. p-Iodoamphetamine as a serotonin depletor in rats. J Pharmacol Exp Ther. 212:1980;115-119.
36. Ali A, Robinson JB. Synthesis, biological evaluation and quantitative structure activity relationship analysis of nuclear-substituted pargylines as competitive inhibitors of MAO-A and MAO-B. J Pharm Pharmacol. 43:1991;750-757.
37. Norinder U, Florvall L, Ross SB. A PLS quantitative structure-activity relationship study of some monoamine oxidase inhibitors of phenylalkylamine type. Eur J Med Chem. 29:1994;191-195.
38. 2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 35:1984;2505-2511.
39. 2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology. 94:1988;213-216.
40. 2 agonists or antagonists? Neuropsychopharmacology. 3:1990;509-517.
41. 2 receptors Implications for treating LSD-induced hallucinogenesis . Psychopharmacology. 98:1989;495-499.
42. Fuller RW. Effects of p-chloroamphetamine on brain serotonin neurons. Neurochem Res. 17:1992;449-456.
43. Mamounas LA, Molliver ME. Evidence for dual serotonergic projections to neocortex Axons from the dorsal and median raphe nuclei are differentially vulnerable to the neurotoxin p-chloroamphetamine (PCA) . Exp Neurol. 102:1988;23-36.
44. O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain Immunocytochemical evidence for neurotoxicity . J Neurosci. 8:1988;2788-2803.
45. Huang X, Marona-Lewicka D, Nichols DE. p-Methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent. Eur J Pharmacol. 229:1992;31-38.
46. Sprague JE, Nichols DE. The monoamine oxidase-B inhibitor l-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J Pharmacol Exp Ther. 273:1995;667-673.
47. Sprague JE, Nichols DE. Inhibition of MAO-B protects against MDMA-induced neurotoxicity in the striatum. Psychopharmacology. 118:1995;357-359.
48. Benmansour S, Brunswick DJ. The MAO-B inhibitor deprenyl, but not the MAO-A inhibitor clorgyline, potentiates the neurotoxicity of p-chloroamphetamine. Brain Res. 650:1994;305-312.
49. Scorza MC, Reyes-Parada M, Silveira R, Viola H, Medina JH, Viana MB, Zangrossi H Jr, Graeff FG. Behavioral effects of the putative anxiolytic (±)-1-(2,5-dimethoxy-4-ethylthiophenyl)-2-aminopropane (ALEPH-2) in rats and mice. Pharmacol Biochem Behav. 54:1996;355-361.
50. Reyes-Parada M, Scorza C, Romero V, Silveira R, Medina JH, Andrus D, Nichols DE, Cassels BK. (±)-1-(2,5-Dimethoxy-4-ethylthiophenyl)-2-aminopropane (ALEPH-2), a novel putative anxiolytic agent lacking affinity for benzodiazepine sites and serotonin-1A receptors. Naunyn-Schmiedebergs Arch Pharmacol. 354:1996;579-585.
51. Nutt DJ, Glue P. Clinical pharmacology of anxiolytics and antidepressants A psychopharmacological perspective . File SE. Psychopharmacology of Anxiolytics and Antidepressants. 1991;1-28 Pergamon Press, New York.